Search

MSK is helping young patients navigate their journey and get the best treatment through specialized counseling, digital connections, and more. “The gratitude I feel is so deep. I’m not just alive; I’m living,” says Desiree Allen.

… Friday, October 1, 2021 Before she was diagnosed with cancer in 2020 at age 31, Desiree Allen was living her best life. “I was in school part-time and working full-time, and I was — and still am — in a long-term relationship,” says the cardiology nurse, now 32. “As a matter of fact, I was having the

In this online discussion, panelists give tips for managing both your physical and mental well-being during the holiday season, especially against the backdrop of the ongoing pandemic.

… Tuesday, December 21, 2021 On Wednesday, December 15, 2021, a panel of Memorial Sloan Kettering Cancer Center (MSK) experts joined the Abyssinian Baptist Church in an online discussion that provided guidance and tips on staying mentally and physically healthy amid uncertainty, especially during this

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.

… Wednesday, February 19, 2025 The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM ) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.  Sarcoma oncologist William Tap, MD , Chief of the

Luis Diaz Jr., MD, Head of the Division of Solid Tumor Oncology, and incumbent of the Grayer Family Chair, and Kojo S.J. Elenitoba-Johnson, MD, Chair of the Department of Pathology and Laboratory Medicine, Member in the Human Oncology Pathogenesis Program (HOPP), and the incumbent of the James Ewing Alumni Chair of Pathology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.

… Tuesday, October 10, 2023 Luis Diaz Jr., MD , Head of the Division of Solid Tumor Oncology, and incumbent of the Grayer Family Chair, and  Kojo S.J. Elenitoba-Johnson, MD , Chair of the Department of Pathology and Laboratory Medicine, Member in the Human Oncology Pathogenesis Program (HOPP), and the

New findings from researchers at the Sloan Kettering Institute suggest that cancer causes may be lurking in the molecule that bridges DNA and protein.

… Monday, August 27, 2018 Summary Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA can inactivate tumor-suppressing proteins and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease. IMPORTANT

New research led by investigators at Memorial Sloan Kettering Cancer Center identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs.

… Wednesday, May 6, 2009 New research led by investigators at Memorial Sloan Kettering Cancer Center (MSKCC) identifies three genes that specifically mediate the metastasis, or spread, of breast cancer to the brain and illuminates the mechanisms by which this spread occurs. The study was published online

A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.

… Friday, February 29, 2008 A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.

… Saturday, December 6, 2014 In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance

This story answers common questions about how your gut microbiota impacts your health, how to protect it, and the impact it has on diseases like cancer.

… Thursday, June 8, 2023 You may have heard the terms “gut microbiota” and “microbiome” and wondered what they mean and why they matter. Many researchers at Memorial Sloan Kettering Cancer Center (MSK) are studying how they influence the health of people with cancer and the general population, too. Here

Proton therapy offers a way to treat pediatric cancers more safely.

… Tuesday, June 18, 2019 Summary Children are especially sensitive to the side effects of conventional radiation therapy. For some pediatric cancers, proton therapy can be used to destroy tumors while minimizing risks. Radiation therapy is quite effective at shrinking or eliminating tumors. But doctors